|Company Name||Amgen Inc.|
On May 22, 2017, Amgen disclosed that approval for Evenity, the Company’s osteoporosis medicine, will be delayed due to heart safety concerns. According to Amgen, a higher percentage of patients who took Evenity experienced cardiovascular side effects after a year, than those who took an older, but approved medicine.
On this news, shares of Amgen fell over 2% on May 22, 2017.
Submit Your Information
If you suffered a loss on your Amgen Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.